Andersen, Mads Hald http://orcid.org/0000-0002-2914-9605
Funding for this research was provided by:
Kræftens Bekæmpelse
Sundhed og Sygdom, Det Frie Forskningsråd
Herlev Hospital
Article History
Received: 22 May 2018
Accepted: 14 June 2018
First Online: 2 July 2018
Compliance with ethical standards
:
: MHA is an author of several filed patent applications based on the use of CCL2, CCL22, PD-L1, PD-L2, arginase, TDO, or IDO for vaccination. The rights of the patent applications have been transferred to Copenhagen University Hospital, Herlev, according to the Danish Law of Public Inventions at Public Research Institutions. The capital region has licensed some of these patents to the company IO Biotech ApS. MHA is a shareholder and board member of the IO Biotech ApS, which has the purpose of developing immune-modulating vaccines for cancer treatment.